Gary L Harris, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 502 S Main St, Smithfield, UT 84335 Phone: 435-563-3222 |
D Barton Avery, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 502 S Main St, Smithfield, UT 84335 Phone: 435-563-3222 |
Dr. Todd Alma Brown, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 291 S Main St, Suite C, Smithfield, UT 84335 Phone: 435-563-6211 Fax: 435-563-6211 |
News Archive
Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cancer cells rely on to adapt and survive when oxygen levels are low.
Thirty years on from the signing of the historic Alma-Ata declaration, the famous rallying call to the global health community, the concept of Primary Health Care, which lay at its heart, is back on the global agenda.
MedQuist Inc., a leading provider of technology-enabled clinical documentation services, continues to support industry best practices for quality standards and metrics. Together with the American Health Information Management Association (AHIMA), the Association for Healthcare Documentation Integrity (AHDI), the Medical Transcription Industry Association (MTIA) and other industry quality leaders, MedQuist contributed to the new Healthcare Documentation Quality Assessment and Management Best Practices just unveiled at the AHDI 32nd Annual Convention and Expo.
Children who sleep better (that is, those who wake up less during night) and those who wake up earlier have more grey matter in their brains (specifically, in eight cortical regions and in the hippocampus), perform better academically, and have a higher level of intelligence (IQ).
Aeterna Zentaris Inc. today announced that the independent Data and Safety Monitoring Board for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015.
› Verified 3 days ago